Literature DB >> 21649468

The numbers of FoxP3+ lymphocytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal status.

Raavi Gupta1, James S Babb, Baljit Singh, Luis Chiriboga, Leonard Liebes, Sylvia Adams, Sandra Demaria.   

Abstract

Regulatory T cells, lymphocytes marked by expression of the transcription factor Forkhead Box Protein P3 (FoxP3), inhibit the activation of tumor-specific T cells in tumor-draining lymph nodes. Immunohistochemical analyses of sentinel lymph nodes (SLNs) from 104 breast cancer patients showed a significant association (p = .0028, Pearson correlation) between the number of FoxP3+ cells and the size of primary breast invasive ductal carcinoma. In contrast, there was no correlation between the number of FoxP3+ cells and the presence of SLN metastases, or other clinicopathological parameters. These results suggest the presence of an immune suppressive environment in SLNs of larger tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21649468      PMCID: PMC3883568          DOI: 10.3109/07357907.2011.585193

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  44 in total

Review 1.  TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.

Authors:  Li Yang; Yanli Pang; Harold L Moses
Journal:  Trends Immunol       Date:  2010-06-01       Impact factor: 16.687

2.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.

Authors:  Michael Gobert; Isabelle Treilleux; Nathalie Bendriss-Vermare; Thomas Bachelot; Sophie Goddard-Leon; Vanessa Arfi; Cathy Biota; Anne Claire Doffin; Isabelle Durand; Daniel Olive; Solène Perez; Nicolas Pasqual; Christelle Faure; Isabelle Ray-Coquard; Alain Puisieux; Christophe Caux; Jean-Yves Blay; Christine Ménétrier-Caux
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

3.  Selective Modulation of Paracortical Dendritic Cells and T-Lymphocytes in Breast Cancer Sentinel Lymph Nodes.

Authors:  Rong Rong Huang; Duan-Ren Wen; Jin Guo; Armando E. Giuliano; Mai Nguyen; Regina Offodile; Stacey Stern; Roderick Turner; Alistair J. Cochran
Journal:  Breast J       Date:  2000-07       Impact factor: 2.431

Review 4.  Regulatory T cells in tumor immunity.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

5.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

6.  Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.

Authors:  Rebecca P Petersen; Michael J Campa; Justin Sperlazza; Debbi Conlon; Mary-Beth Joshi; David H Harpole; Edward F Patz
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

Review 7.  The anticancer immune response: indispensable for therapeutic success?

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Fabrice André; Antoine Tesniere; Guido Kroemer
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

8.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

9.  Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma.

Authors:  Kazuo Matsuura; Yoshiyuki Yamaguchi; Hideaki Ueno; Akihiko Osaki; Koji Arihiro; Tetsuya Toge
Journal:  Cancer       Date:  2006-03-15       Impact factor: 6.860

10.  Down-regulation of the CD3-zeta chain in sentinel node biopsies from breast cancer patients.

Authors:  Jana Schüle; Leif Bergkvist; Leif Håkansson; Bertil Gustafsson; Annika Håkansson
Journal:  Breast Cancer Res Treat       Date:  2002-07       Impact factor: 4.872

View more
  3 in total

1.  Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.

Authors:  Sylvia Adams; Lina Kozhaya; Frank Martiniuk; Tze-Chiang Meng; Luis Chiriboga; Leonard Liebes; Tsivia Hochman; Nicholas Shuman; Deborah Axelrod; James Speyer; Yelena Novik; Amy Tiersten; Judith D Goldberg; Silvia C Formenti; Nina Bhardwaj; Derya Unutmaz; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2012-07-05       Impact factor: 12.531

2.  Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer.

Authors:  M Miyan; J Schmidt-Mende; R Kiessling; I Poschke; J de Boniface
Journal:  J Transl Med       Date:  2016-07-29       Impact factor: 5.531

3.  Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.

Authors:  Guido Henke; Michael Knauer; Karin Ribi; Stefanie Hayoz; Marie-Aline Gérard; Thomas Ruhstaller; Daniel R Zwahlen; Simone Muenst; Markus Ackerknecht; Hanne Hawle; Florian Fitzal; Michael Gnant; Zoltan Mátrai; Bettina Ballardini; Andreas Gyr; Christian Kurzeder; Walter P Weber
Journal:  Trials       Date:  2018-12-04       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.